PTM Monitoring - Deamidation

Dr. Harsha Gunawardena works on developing and applying MS-based quantitative proteomics technologies and bioinformatics to understand system-wide protein expression and PTM differences. One of his major interests is the implementation of disruptive technologies to accelerate discovery research in biopharma.

Dr. Gunawardena believes it is critically important to adopt high-throughput methods to identify glycosylation profiles. His laboratory is investigating the use of HRIM-MS as a high-throughput, high-resolution alternative for LC-based glycan analysis, enabling more comprehensive data sets with reduced analysis times.

Posttranslational modifications (PTMs) to peptides  can disrupt secondary and tertiary protein structure leading to changes in safety or efficacy of protein-based therapeutics. Monitoring of PTMs to ensure production and distribution of safe and efficacious biotherapeutics requires robust and high-throughput analytical techniques capable of detecting extremely small differences in structure.  

Conventional methods for biopharmaceutical drug characterization rely heavily on lengthy LC separations(60-90 minutes) with complex data sets & time-consuming analysis ultimately resulting in delayed project turnaround.

Implementing MOBIE into a traditional LC-MS workflow reduced reliance on LC. Decreasing the overall analysis time and providing an orthogonal mode of identification with increased accuracy in peptide isomerization & peptide mapping. Further, incorporating use of streamlined Protein Metrics' data processing aligned with customer's existing workflows provides one-click report generation for analysis.